Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 4
2008 2
2009 1
2010 6
2011 4
2012 6
2013 12
2014 15
2015 10
2016 14
2017 8
2018 7
2019 7
2020 9
2021 18
2022 8
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Syntenin-1-mediated arthritogenicity is advanced by reprogramming RA metabolic macrophages and Th1 cells.
Meyer A, Sienes RE, Nijim W, Zanotti B, Umar S, Volin MV, Van Raemdonck K, Lewis M, Pitzalis C, Arami S, Al-Awqati M, Chang HJ, Jetanalin P, Schett G, Sweiss N, Shahrara S. Meyer A, et al. Among authors: van raemdonck k. Ann Rheum Dis. 2023 Apr;82(4):483-495. doi: 10.1136/ard-2022-223284. Epub 2023 Jan 2. Ann Rheum Dis. 2023. PMID: 36593091 Free PMC article.
A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs.
Bogaert B, Sauvage F, Guagliardo R, Muntean C, Nguyen VP, Pottie E, Wels M, Minnaert AK, De Rycke R, Yang Q, Peer D, Sanders N, Remaut K, Paulus YM, Stove C, De Smedt SC, Raemdonck K. Bogaert B, et al. Among authors: raemdonck k. J Control Release. 2022 Oct;350:256-270. doi: 10.1016/j.jconrel.2022.08.009. Epub 2022 Aug 24. J Control Release. 2022. PMID: 35963467 Free PMC article.
Non-invasive cell-tracking methods for adoptive T cell therapies.
Van Hoeck J, Vanhove C, De Smedt SC, Raemdonck K. Van Hoeck J, et al. Among authors: raemdonck k. Drug Discov Today. 2022 Mar;27(3):793-807. doi: 10.1016/j.drudis.2021.10.012. Epub 2021 Oct 27. Drug Discov Today. 2022. PMID: 34718210 Review.
Therapeutic and diagnostic applications of extracellular vesicles.
Stremersch S, De Smedt SC, Raemdonck K. Stremersch S, et al. Among authors: raemdonck k. J Control Release. 2016 Dec 28;244(Pt B):167-183. doi: 10.1016/j.jconrel.2016.07.054. Epub 2016 Aug 2. J Control Release. 2016. PMID: 27491882 Review.
A personalized view on cancer immunotherapy.
Wayteck L, Breckpot K, Demeester J, De Smedt SC, Raemdonck K. Wayteck L, et al. Among authors: raemdonck k. Cancer Lett. 2014 Sep 28;352(1):113-25. doi: 10.1016/j.canlet.2013.09.016. Epub 2013 Sep 17. Cancer Lett. 2014. PMID: 24051308 Review.
CXCR3 ligands in disease and therapy.
Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S. Van Raemdonck K, et al. Cytokine Growth Factor Rev. 2015 Jun;26(3):311-27. doi: 10.1016/j.cytogfr.2014.11.009. Epub 2014 Nov 22. Cytokine Growth Factor Rev. 2015. PMID: 25498524 Review.
Pulmonary surfactant as a versatile biomaterial to fight COVID-19.
Herman L, De Smedt SC, Raemdonck K. Herman L, et al. Among authors: raemdonck k. J Control Release. 2022 Feb;342:170-188. doi: 10.1016/j.jconrel.2021.11.023. Epub 2021 Nov 20. J Control Release. 2022. PMID: 34813878 Free PMC article. Review.
120 results